Shares of Prenetics Global Limited (NASDAQ:PRE - Get Free Report) have received an average recommendation of "Moderate Buy" from the eight analysts that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, six have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $37.17.
A number of equities research analysts recently weighed in on the company. Maxim Group assumed coverage on Prenetics Global in a research report on Monday, October 26th. They set a "buy" rating and a $41.00 target price on the stock. Craig Hallum started coverage on Prenetics Global in a report on Thursday, September 17th. They issued a "buy" rating and a $40.00 price target for the company. Wall Street Zen upgraded Prenetics Global from a "sell" rating to a "hold" rating in a research report on Saturday, August 22nd. Lucid Cap Mkts upgraded Prenetics Global to a "strong-buy" rating in a research report on Monday, October 12th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Prenetics Global in a report on Thursday, October 15th.
Read Our Latest Report on PRE
Insiders Place Their Bets
In other news, CEO Danny Sheng Wu Yeung bought 17,181 shares of Prenetics Global stock in a transaction that occurred on Monday, August 24th. The stock was purchased at an average cost of $21.23 per share, with a total value of $364,752.63. Following the completion of the transaction, the chief executive officer directly owned 112,416 shares in the company, valued at $2,386,591.68. This trade represents a 18.04% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Brian Rosin bought 18,000 shares of Prenetics Global stock in a transaction that occurred on Monday, August 24th. The stock was purchased at an average cost of $21.19 per share, with a total value of $381,420.00. Following the completion of the transaction, the chief financial officer owned 18,000 shares of the company's stock, valued at $381,420. This trade represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders purchased 47,781 shares of company stock valued at $999,778 over the last 90 days.
Hedge Funds Weigh In On Prenetics Global
A number of hedge funds have recently made changes to their positions in PRE. State of Wyoming bought a new position in shares of Prenetics Global during the 1st quarter worth about $48,000. Stevens Capital Partners boosted its position in shares of Prenetics Global by 9.0% during the 3rd quarter. Stevens Capital Partners now owns 30,674 shares of the company's stock valued at $709,000 after acquiring an additional 2,527 shares in the last quarter. Operose Advisors LLC bought a new stake in Prenetics Global in the second quarter valued at about $129,000. Goldman Sachs Group Inc. bought a new stake in Prenetics Global in the third quarter valued at about $253,000. Finally, State Street Corp bought a new stake in Prenetics Global in the third quarter valued at about $264,000. Institutional investors and hedge funds own 25.01% of the company's stock.
Prenetics Global Price Performance
Shares of Prenetics Global stock opened at $15.48 on Friday. The company has a market cap of $261.15 million, a PE ratio of -3.72 and a beta of 0.40. The firm has a fifty day moving average price of $20.26 and a two-hundred day moving average price of $19.55. Prenetics Global has a fifty-two week low of $11.36 and a fifty-two week high of $27.24.
Prenetics Global (NASDAQ:PRE - Get Free Report) last posted its quarterly earnings data on Wednesday, August 19th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.84) by $0.31. Prenetics Global had a negative net margin of 47.43% and a negative return on equity of 21.41%. The company had revenue of $46.49 million for the quarter, compared to the consensus estimate of $49.85 million. Analysts expect that Prenetics Global will post -2.36 earnings per share for the current fiscal year.
About Prenetics Global
(
Get Free Report)
Prenetics Global Limited is a health sciences company focused on consumer wellness and health-related products. Its portfolio includes IM8, a consumer wellness brand offering nutritional supplements, and CircleDNA, a genetic testing service that provides reports on health, wellness and ancestry. The company has also operated clinical genomic testing services and provided COVID-19 testing during the pandemic. Its business has since shifted toward consumer health and wellness. Prenetics was founded in 2014 and is led by co-founder and Chief Executive Officer Danny Yeung.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Prenetics Global, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prenetics Global wasn't on the list.
While Prenetics Global currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.